Pinzani V, Mauboussin J M, Hillaire-Buys D, Moati L, Barbuat C, Jourdan J, Blayac J P, Balmès P
Service de Pneumologie-Médecine A, CHU Nîmes.
Ann Med Interne (Paris). 1995;146(7):505-9.
The treatment and the prevention of Pneumocystis carinii pneumonia (PCP) is based on trimethoprim-sulfamethoxazole. However, hypersensitivity reactions occur often in HIV-infected patients. In this study, clinical and biological parameters of 27 PCP-patients treated by this drug association were analyzed. We divided the drug reactions into two groups according to the severity. A drug reaction occurred in 59.2% of the patients and was note as a mild reaction in 18.5% of the cases and as a severe reaction in 40.7%. An initial high eosinophil count was noted in patients who may present future drug reaction. This difference was more significant in patients who may present severe drug reaction. No other clinical or biological factors were predictive of hypersensitivity. The immune status of HIV-disease, drug therapy, and drug mechanisms were discussed.
卡氏肺孢子虫肺炎(PCP)的治疗和预防以甲氧苄啶 - 磺胺甲恶唑为基础。然而,HIV感染患者中经常发生超敏反应。在本研究中,分析了27例接受这种药物联合治疗的PCP患者的临床和生物学参数。我们根据严重程度将药物反应分为两组。59.2%的患者发生了药物反应,其中18.5%的病例为轻度反应,40.7%为严重反应。在可能出现未来药物反应的患者中,最初嗜酸性粒细胞计数较高。这种差异在可能出现严重药物反应的患者中更为显著。没有其他临床或生物学因素可预测超敏反应。讨论了HIV疾病的免疫状态、药物治疗和药物作用机制。